Bruker Also Announces First MPI Customer Installation, new PCI
Center in Singapore
SEOUL, South Korea--(BUSINESS WIRE)--
At the 2014 World Molecular Imaging Congress (WMIC, www.wmis.org),
Bruker today introduces new products for improved performance and
customer experience in preclinical imaging, and announces related
achievements:
NEW PRODUCT: SkyScan™
1278, the world’s fastest, low-dose, high-resolution
micro-CT: With the launch of the next-generation SkyScan 1278
micro-CT system for in vivo X-ray computed tomography, Bruker is
addressing the latest needs of preclinical imaging scientists striving
to reduce the radiation dose used in animal studies, while maintaining
highest image quality. As part of the development, Bruker has created a
new micro-CT spatial beam shaper, which reduces the absorbed dose by up
to five times, while maintaining high quality image output.
The SkyScan 1278 has a highly sensitive flat-panel
detector that is able to deliver images of mouse heart and lung
activities even without a contrast agent. Such images allow the user to
explore cardiac and respiratory function, while reducing animal stress
and the cost of the study. A full-body animal scan can take 8 seconds or
less, reducing run times and increasing the speed of data collection.
FIRST CUSTOMER INSTALLATION: Bruker announces the first customer
installation of its MPI
PreClinical, a preclinical Magnetic Particle Imaging (MPI)
scanner, at the University Medical Center Hamburg-Eppendorf (UKE),
Germany. Significantly, this marks the first time that MPI technology
has been delivered in a commercial system. Preclinical MPI is an
entirely new technology for in vivo imaging of small animals used
in translational research.
The new MPI PreClinical was announced in 2013 and is the
result of Bruker’s collaboration with
Royal Philips
(NYSE: PHG, AEX:
PHIA). It combines Bruker’s leadership in preclinical imaging with
Philips’ strength in medical imaging. MPI was invented by scientists at
Philips and uses the detection of magnetic iron-oxide nanoparticles
injected into the bloodstream to produce three-dimensional images at
millisecond intervals, providing the potential for real-time 3D imaging in
vivo. MPI’s high time-resolution allows researchers to investigate a
range of dynamic issues, e.g. in cardiovascular research, which cannot
be studied using other techniques.
NEW PRODUCT: BioSpec 21T Ultra-high Field MRI with CryoProbe Bruker
introduces the BioSpec®
210/11, a new 21 Tesla ultra-high field MRI with CryoProbe™
for small animal Magnetic Resonance Imaging (MRI). As in vivo
investigation shifts from organ and tissue imaging to cellular and
molecular research, a significant boost in sensitivity and resolution is
required. With the unique 21T MRI, Bruker customers can set new
performance benchmarks and gain new insights in preclinical research.
The BioSpec 210/11 is based on Bruker’s proven 21 Tesla 11
cm USR™ magnet that is already successfully used in
FT-mass spectrometry. UltraShield™ magnet technology
reduces magnetic stray fields, while Bruker’s active refrigeration
technology virtually eliminates cryogen refills, reducing down-time and
user maintenance efforts.
NEW PCI CENTER: Bruker has enjoyed a long-term partnership with
the Singapore Bioimaging Consortium (SBIC), and the new SBIC-Bruker
Preclinical Imaging (PCI) Center in Singapore consolidates bio-imaging
capabilities to promote innovation in biological research. The PCI
facility, due to open in October 2014, will provide advanced
demonstration, training and applications support for Bruker’s
industry-leading preclinical portfolio and multi-modal imaging
platforms. By combining PCI technologies and modalities, the center will
play a key role in promoting the application of complementary imaging
information.
Wulf I. Jung
, Ph.D., President of Bruker’s Preclinical Imaging division,
stated: “At WMIC 2014, we continue our Innovation with Integrity
to enable the success of our customers. With differentiated, high
performance products we enable novel preclinical imaging research and
gain access to new markets, while maintaining our excellent reputation
in the scientific research community.”
About Bruker Corporation
Bruker (NASDAQ: BRKR) is a leading provider of high-performance
scientific instruments and solutions for molecular and materials
research, as well as for in vitro diagnostics, industrial and
applied analysis.
For more information on Bruker’s Preclinical Imaging division, please
visit www.bruker.com/preclinicalimaging.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140917005787/en/
Source: Bruker Corporation